P¼.133; Q4:1.221 (1.049-1.420), P¼.010). However, the odds ratio for Qmax<10 mL/sec was not significantly different between free T4 quartile groups after adjusting confounding factors. In propensity score matched analysis (matched for age, metabolic syndrome, testosterone, and body mass index at a 1:1 ratio), 1362 cases (Q4 of free T4) and 1362 control subjects (Q1, Q2, and Q3 of free T4) were included for comparison. The ratio of prostate volume !30 mL (15.1% vs. 19.3%, P ¼ .004) and mean prostate volume (23.7AE6.7 vs. 24.6AE7.3 mL, P¼.001) was higher in the case group than in the control group. Qmax and IPSS were not different between case and control groups. TSH was not significantly related to IPSS, Qmax, and total prostate volume in univariate and multivariate analyses.
INTRODUCTION AND OBJECTIVES: The steroid 5-[alpha]
reductase type 2 (SRD5A2) is critical for prostatic development and growth. One-third of men are resistant to 5ARI therapies. We previously showed that expression of SRD5A2 is not static. Here we wished to identify whether absence of prostatic SRD5A2, when androgenic pathways are blocked, leads to modification of alternate hormonal pathways.
METHODS: Prostatic samples were obtained from patients with symptomatic BPH undergoing transurethral resection of prostate (TURP) surgery. Methylation of SRD5A2 promoter was assessed using Methylated CpG Island Recovery Assay (MIRA). RNA was extracted for whole-transcriptome profiling analysis by Illumina Human BeadChip Arrays. Prostatic protein expression of SRD5A2, androgen receptor (AR), estrogen receptor (ER) subunits, and aromatase were determined in a panel of six BPH patients by Western blot, immunohistochemistry (IHC), and ELISA assays. Prostatic levels of testosterone (T), dihydrotestosterone (DHT), estradiol (E) were measured by HPLC-MS. In in vitro study, primary prostatic stroma cells and epithelial cell line, BPH-1, were cultured and treated with TNF- [alpha] and IL-6, and mRNA levels were determined by qPCR.
RESULTS: In prostate specimens that were methylated at the SRD5A2 promoter locus, estrogen response genes were identified as one of the most significantly upregulated gene family members as determined by gene expression analysis. The levels of T, E and aromatase were significantly upregulated, while DHT was significantly decreased. Absence of SRD5A2 significantly upregulated the phosphorylation of ERa (pERa), but did not significantly affect the levels of total ERa, total ERb or pERb. In primary prostatic stromal cells, administration of TNF-a, but not IL-6, suppressed the level of SRD5A2 and upregulated aromatase activity and ERa expression. However, treatment of prostatic epithelial cells with TNF-a or IL-6 did not change the androgenic or estrogenic signalling, suggesting that stromal cells regulate the androgenic to estrogenic switch when SRD5A2 is absent. CONCLUSIONS: Our study demonstrates for the first time that there is an androgenic to estrogenic switch when SRD5A2 is absent in the prostate gland. Somatic epigenetic silencing of SRD5A2 changes the prostatic hormonal milieu, and may modulate prostatic homeostasis and growth. Targeting the aromatase-estrogen-ER axis may serve as an effective treatment strategy in BPH patients who lack SRD5A2 expression. METHODS: RNA-seq was performed on BPH1 cells treated with E2 (binds ERa and ERb), SERMs that bind ERb (3b-diol, DPN, and WAY20070) and ERa (PPT) to identify genes specifically regulated by either ERa or ERb. Sequences were mapped and assembled using TopHat, HTSeq, and edgeR. Genes reported were greater than 2-fold change over vehicle control with p-value < 0.05. CRISPR/Cas9 was used to knockout ERa and/or ERb in BPH-1 cells to further validate ERspecific gene regulation as well as ER dimerization using Bioluminescence resonance energy transfer techniques.
RESULTS: RNA-seq analysis of BPH1 cells treated with ER agonists revealed both overlapping and distinct gene expression profiles for each compound. By examining the overlap of genes induced or repressed by both the natural and synthetic compounds specific for each receptor, we have identified 144 ERa-specific, 222 ERb-specific, and 42 ERa/ERb-heterodimer genes. Luciferase assays in the CRISPR knockout cells confirm the receptor specificity of the synthetic compounds used in this study. Additionally, dimerization studies confirm the contribution of ERa and/or ERb to the regulation of gene expression.
CONCLUSIONS: Using E2 and SERMs, we were able to identify and validate ERa-and ERb-regulated genes in benign prostate cells. Further studies assessing these estrogen-regulated genes will provide a basis for biomarkers in the study of BPH/LUTD. Furthermore, given the opposing roles of ERa and ERb, these genes will allow us to further assess the function of ER in disease promotion in patients and animal models as well as monitor the efficacy of therapeutic SERMs in the treatment of BPH/LUTS.
Source of Funding: 5K12DK100022 U54DK104310 R01DK093690

MP17-09 CXCL12-CXCR4 AXIS ACTIVATION PROMOTES COP II VESICLE-MEDIATED SECRETION OF COLLAGEN BY PROSTATE MYOFIBROBLASTS
Susan Patalano-Salsman, Jose A. Rodriguez-Nieves, Diego Almanza, Amy Avery, Andrew Judell-Halfpenney, Todd Riley, Jill Macoska*, Boston, MA INTRODUCTION AND OBJECTIVES: Factors that promote lower urinary tract voiding dysfunction (LUTD) in aging men include excessive prostatic proliferation and muscle contraction. Recent studies suggest that tissue fibrosis, e.g., peri-urethral collagen accumulation, may also contribute to LUTD. Our group recently reported that activation of the CXCL12/CXCR4 axis and downstream MEK/ERK activation, as well as canonical TGFb/TGFbR axis activation and downstream Smad3 activation, promote prostate fibroblast to myofibroblast phenoconversion and collagen production. Based on this finding, we hypothesized that downstream MEK/ERK and Smad signaling would converge at the transcriptional level to promote the activation of genes encoding pro-fibrotic proteins. To test this, RNA sequencing analysis was performed on prostate fibroblasts treated with CXCL12 or TGFb.
METHODS: Prostate fibroblasts were treated with 4ng/ml TGFb or 100pM CXCL12 for 12 hrs (RNA) or 24, 48 and 72 hrs (protein). Total RNA e214 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 was purified and subjected to qRT-PCR or RNASeq. Sequence data was pipelined through the Bowtie/TopHat/Cufflinks/CummeRbund (Tuxedo) packages. Pathview v1.10.1 and Cytoscape were used to perform Kegg pathway and network analysis, respectively. Immunoblot analysis was performed using whole protein lysates or concentrated conditioned media. RESULTS: RNASeq analysis showed that prostate fibroblasts treated with CXCL12 up-regulated the transcript levels of genes that encoded members of the Cullin-RING 3 (CRL3) ubiquitin ligase family of proteins. These proteins form COPII vesicles that transport procollagen from the endoplasmic reticulum to the cell membrane and extracellular space. Western blot analysis showed that CXCL12-treated cells upregulated CRL3 proteins and secreted higher levels of procollagen compared to vehicle and TGFb-treated cells. Procollagen secretion was ablated upon treatment with AMD3100, a CXCR4 antagonist, demonstrating that the observed increased collagen secretion was specifically coupled to CXCL12/CXCR4 axis activation.
CONCLUSIONS: The results of these studies are consistent with our hypothesis and present a major new discovery: Activation of the CXCL12/CXCR4 axis promotes fibrosis by increasing both the expression and secretion of collagen. Since the stromal compartment does not express PSA, epithelial barrier integrity in BPH nodules might be compromised through loss of cell junctions, resulting in the leakage of PSA and other secreted proteins into the stromal compartment and subsequently promoting BPH pathogenesis. E-cadherin, an important cell junction regulator, is found to be down-regulated in epithelial cells in clinical BPH specimens. Whether E-cadherin downregulation affects epithelial barrier permeability is unknown. This research is aimed at examining epithelial barrier permeability change in BPH and exploring the potential role of E-cadherin in prostatic luminal epithelial permeability.
METHODS: Explants derived from BPH patients were used to study epithelial barrier permeability in BPH nodules and its normal adjacent tissues by FITC-dextran assay. Normal prostate luminal epithelial cell line BHPrE1 was utilized to perform in vitro studies. Two independent siRNAs were used to knockdown E-cadherin expression. Permeability of BHPrE1 cell monolayers in trans-well inserts was evaluated by transepithelium electrical resistant (TER) assay and FITC-dextran trans-well assay. Cell viability was checked by cell counting assay and MTT assay. Expression of E-cadherin and tight junction proteins following siRNAs treatment were determined by reverse transcription-polymerase chain reaction (RT-PCR) and western-blot (WB).
RESULTS: FITC-dextran assay detected an increased epithelial barrier permeability in BPH tissues but not in the adjacent normal prostate in explants derived from BPH patients. Knockdown of E-cadherin in BHPrE1 cells decreased TER and increased FITC-dextran diffusion, indicating that E-cadherin knockdown disrupted epithelial barrier and increased monolayer permeability. E-cadherin knockdown had no impact on cell viability. E-cadherin knockdown also did not affect the expression of tight junction proteins ZO-1, ZO-2 and ZO-3.
CONCLUSIONS: Epithelial barrier permeability was increased in BPH and loss of E-cadherin is potentially an important underlying mechanism. Our results suggest blocking E-cadherin loss could be a potential approach to prevent or treat BPH.
Source of Funding: 1U54 DK112079 and 1R56 DK107492
MP17-11 CONTRIBUTIONS OF PROSTATE VOLUME AND FIBROSIS TO BLADDER OUTLET OBSTRUCTION
Matthew D Grimes*, Will Lyon, Sijian Wang, Lori M Gettle, Wade A Bushman, Madison, WI INTRODUCTION AND OBJECTIVES: It has been proposed that prostatic fibrosis contributes to bladder outlet obstruction in men with BPH/LUTS. We used preoperative urodynamics and CT imaging to evaluate the contributions of prostatic enlargement and fibrosis to obstruction in a cohort of men who underwent surgery for BPH/LUTS. Prostate volume and radiodensity were determined from the preoperative CT scan. Hounsfield units (HU), a quantitative measure of radiodensity on CT scans used frequently as a surrogate marker for liver and lung fibrosis, was used as a surrogate marker for prostate fibrosis.
METHODS: We identified 34 men (mean age of 66 yrs, range 48-93 yrs) with complete pre-operative urodynamic evaluation for whom noncontrast axial pelvic CT scan images were available. Prostate volume was calculated using the formula for ellipsoid volume (L x W x H x 0.52). Mean prostate HU was determined by averaging the HU of ellipsoid selections of the proximal, middle, and distal prostate. The bladder outlet obstructive index (BOOI) was calculated from the formula P det Q max -2Q max and used to classify patients as obstructed (BOOI ! 40), equivocal or unobstructed (BOOI < 20) . Ten men aged 20-40 years who underwent non-contrast axial CT scanning for flank pain were used as controls.
RESULTS: Mean BOOI was 56 (22 obstructed, 7 equivocal and 5 unobstructed). Mean prostate volume was significantly greater in patients with BPH/LUTS (mean 62 cc; range 19-217 cc) than in controls (mean 24 cc; range 14-33 cc) (<0.0001). Linear regression analysis revealed a significant positive relationship between volume and BOOI (p-value ¼ 0.04) in patients with BPH/LUTS. Mean prostate HU was significantly higher in men with BPH/LUTS (mean 37 HU, standard deviation 6 HU, range 28-49 HU) compared to controls (mean 41 HU, standard deviation 5 HU, range 35-51 HU) (p¼0.04) but linear regression analysis revealed no significant positive relationship between HU and BOOI (p ¼ 0.32).
CONCLUSIONS: Our studies affirm that prostate volume is significantly associated with urodynamic evidence of obstruction among men with BPH/LUTS. Prostatic radiodensity was significantly higher in men with BPH/LUTS compared to young healthy controls, but we found no significant association bettween prostate radiodensity and urodynamic evidence of obstruction in men with BPH/LUTS. Source of Funding: VA Merit Award: 1010 BX003454-01
MP17-12 TH2 CYTOKINES PROMOTE MYOFIBROBLAST PHENOCONVERSION AND PROSTATIC FIBROSIS
Mehrnaz Gharaee-Kermani*, Jill Macoska, Boston, MA INTRODUCTION AND OBJECTIVES: A growing number of recent studies associate lower urinary tract dysfunction (LUTD) with concurrent tissue fibrosis. Other studies have described profuse inflammatory infiltrate of benign prostatic hyperplasia (BPH) tissues, and that Th2 cytokines, particularly IL-4 and IL-13, are produced and secreted by infiltrating T-cells in these tissues. Because Th2 cytokines have been shown to mediate tissue fibrosis in the lung and liver, we hypothesized that Th2 cytokines secreted by inflammatory infiltrate may promote collagen accumulation and fibrosis in the prostate.
METHODS: N1 immortalized and primary prostate fibroblasts and lung fibroblasts (the later included as positive controls) were grown in serum free defined media supplemented with vehicle, TGFbeta, IL-4, and IL-13 alone or in combination with or without IL-4 or IL-13 inhibitors. Cells were evaluated by immunofluorescence for alphaSMA and collagen expression in situ, by immunoblot for IL-4Ralpha and IL13R1alpha expression, by WST assay for cell proliferation, by ELISA for protein expression, or by Sircol assay for collagen production.
RESULTS: Prostate and lung fibroblasts expressed the IL-4Ral-pha and IL-13R1alpha receptor proteins. N1 and primary prostate and lung fibroblasts underwent myofibroblast phenoconversion and significantly
